Fundraising FoxModulus Therapeutics
acquired by Ginkgo BioworksSeattle, US · Founded 2020 · Delaware corporation · 3 known investors
Find your way into Modulus Therapeutics
Sign up to see every warm intro you have to Modulus Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Modulus Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Ginkgo Bioworks April 2024 · terms undisclosed · source ↗
Modulus Therapeutics was a Seattle biotech spun out of the Allen Institute for AI that used machine learning to engineer immune cells, initially NK cells for cancer, later shifting toward autoimmune cell therapies.
Founders & leadership
Investors · 3
How we know: Madrona Venture Group's portfolio page · a partner's Signal profile · funding news · unite.ai · the VCSheet dataset · Not right? Tell us
How we know: a partner's Signal profile · funding news · press coverage · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$3.8M disclosed across 1 round · 2021
▶$3.8MraisedJul 2021 · 9 investors · BiotechnologyRule 506(b)
- Bryce R DainesExecutive Officer, Director
- Max C DarnellExecutive Officer, Director
- Offering amount
- $3.8M
- Amount sold
- $3.8M
- Minimum investment
- $125K
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Modulus Therapeutics do?
- Modulus Therapeutics was a Seattle biotech spun out of the Allen Institute for AI that used machine learning to engineer immune cells, initially NK cells for cancer, later shifting toward autoimmune cell therapies.
- Who are Modulus Therapeutics's investors?
- Modulus Therapeutics's investors include Madrona Venture Group, KdT Ventures.
- How much funding has Modulus Therapeutics raised?
- Modulus Therapeutics has disclosed $3.8M raised across 1 round.
- Who acquired Modulus Therapeutics?
- Modulus Therapeutics was acquired by Ginkgo Bioworks.
- Where is Modulus Therapeutics headquartered?
- Modulus Therapeutics is headquartered in Seattle, US.